S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
NASDAQ:OPK

OPKO Health (OPK) Stock Price, News & Analysis

$1.23
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
$1.20
$1.24
50-Day Range
$0.87
$1.40
52-Week Range
$0.85
$2.24
Volume
2.66 million shs
Average Volume
13.71 million shs
Market Capitalization
$857.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.73

OPKO Health MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
202.8% Upside
$3.73 Price Target
Short Interest
Healthy
28.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.78mentions of OPKO Health in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$4.42 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.33) to ($0.21) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.74 out of 5 stars

Medical Sector

54th out of 911 stocks

Pharmaceutical Preparations Industry

18th out of 411 stocks

OPK stock logo

About OPKO Health Stock (NASDAQ:OPK)

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

OPK Stock Price History

OPK Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
OPK Mar 2024 0.500 put
Q4 2023 OPKO Health Inc Earnings Call
OPKO Health Inc (OPK) Reports Fourth Quarter 2023 Results
OPKO Health's Earnings Outlook
Opko Health Inc
See More Headlines
Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/19/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:OPK
CUSIP
68375N10
Employees
3,930
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.73
High Stock Price Target
$5.40
Low Stock Price Target
$1.50
Potential Upside/Downside
+202.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-188,860,000.00
Pretax Margin
-21.35%

Debt

Sales & Book Value

Annual Sales
$863.50 million
Book Value
$1.80 per share

Miscellaneous

Free Float
367,594,000
Market Cap
$857.30 million
Optionable
Optionable
Beta
1.82
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Phillip Frost Ph.D. (Age 88)
    Chairman & CEO
    Comp: $1.45M
  • Dr. Jane H. Hsiao M.B.A. (Age 77)
    Ph.D., Vice Chairman & Chief Technical Officer
    Comp: $1.36M
  • Dr. Elias Adam Zerhouni M.D. (Age 73)
    President & Vice Chairman
    Comp: $1.36M
  • Mr. Adam E. Logal (Age 46)
    Senior VP, CFO, Chief Accounting Officer & Treasurer
    Comp: $1.09M
  • Mr. Steven D. Rubin Esq. (Age 64)
    J.D., Executive VP of Administration & Director
    Comp: $1.22M
  • Dr. Akhtar Ashfaq FACP
    FASN, M.D., Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal
  • Dr. Gary J. Nabel M.D. (Age 69)
    Ph.D., Chief Innovation Officer & Director
  • Dr. Charles W. Bishop (Age 72)
    Chief Executive Officer of OPKO Renal
  • Dr. Antonio F. Cruz (Age 71)
    President of Transition Therapeutics
  • Mr. Hans Berner
    President of OPKO Health Iberoamerica

OPK Stock Analysis - Frequently Asked Questions

Should I buy or sell OPKO Health stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPK shares.
View OPK analyst ratings
or view top-rated stocks.

What is OPKO Health's stock price target for 2024?

3 brokerages have issued 1 year price targets for OPKO Health's stock. Their OPK share price targets range from $1.50 to $5.40. On average, they expect the company's share price to reach $3.73 in the next twelve months. This suggests a possible upside of 202.8% from the stock's current price.
View analysts price targets for OPK
or view top-rated stocks among Wall Street analysts.

How have OPK shares performed in 2024?

OPKO Health's stock was trading at $1.51 at the beginning of the year. Since then, OPK stock has decreased by 18.5% and is now trading at $1.23.
View the best growth stocks for 2024 here
.

When is OPKO Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our OPK earnings forecast
.

How were OPKO Health's earnings last quarter?

OPKO Health, Inc. (NASDAQ:OPK) announced its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.09) EPS for the quarter, meeting analysts' consensus estimates of ($0.09). The biotechnology company earned $181.90 million during the quarter, compared to analyst estimates of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative trailing twelve-month return on equity of 12.69%. The company's revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.11) EPS.

What ETFs hold OPKO Health's stock?
What is Philip Frost's approval rating as OPKO Health's CEO?

21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OPKO Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).

Who are OPKO Health's major shareholders?

OPKO Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.11%) and Moseley Investment Management Inc. (0.00%). Insiders that own company stock include Elias A Zerhouni, Gary J Nabel, Jane Ph D Hsiao, Jon R Cohen, Opko Health, Inc, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Richard M Krasno, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends
.

How do I buy shares of OPKO Health?

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPK) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners